This is consistent with the in vivo tumor growth inhibition shown in Figures 6 and 7, in which RS17 or B6H12 treatment inhibited HepG2 growth by blocking the interactions between CD47 on HepG2 and SIRPα on mouse macrophages. The gene discussed is SIRPA; the disease is neoplasm.